Furthermore, EGCG treatment resulted in a decrease in the levels of platelet-type phosphofructokinase (PFKP) and pyruvate kinase M2 (PKM2) in pancreatic tumor xenograft homogenates acquired from mice [244]. The gene discussed is PFKP; the disease is pancreatic neoplasm.